Taguchi, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Associate Professor

Career 【 Display / hide

  • 2010.04
    -
    2011.03

    日本学術振興会特別研究員

  • 2011.04
    -
    2013.03

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013.04
    -
    2017.03

    崇城大学 , 薬学部, 助教

  • 2018.04
    -
    2021.03

    慶應義塾大学, 薬学部, 専任講師

  • 2021.04
    -
    Present

    慶應義塾大学, 薬学部, 准教授

Academic Background 【 Display / hide

  • 2006.03

    Kumamoto University, 薬学部

    University, Graduated

  • 2008.03

    Kumamoto University

    Graduate School, Completed, Master's course

  • 2011.03

    Kumamoto University

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士 (薬学), 熊本大学, 2011.03

Licenses and Qualifications 【 Display / hide

  • 薬剤師, 2006.04

 

Books 【 Display / hide

  • Carbon monoxide-bound Hemoglobin-Vesicles: Current facts and potential medical applications.

    Taguchi K, Matsumoto K, Sakai H, Maruyama T, Otagiri M, World Scientific Publishing Co. Pte. Ltd., 2021.12

    Scope: Chapter 6.10.,  Contact page: 849-865

  • DDS先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017

    Scope: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015

    Scope: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013

    Scope: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013

    Scope: Chapter 6, pp.139-62

Papers 【 Display / hide

  • Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection.

    Iketani O, Komeya A, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Kizu J, Hasegawa N

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 28 ( 1 ) 61 - 66 2022.01

    Research paper (scientific journal), Accepted,  ISSN  1341-321X

  • Long-term pharmaceutical stability of liposome-encapsulated methemoglobin as an antidote for cyanide poisoning

    Suzuki Y., Taguchi K., Kure T., Enoki Y., Otagiri M., Sakai H., Matsumoto K.

    International Journal of Pharmaceutics (International Journal of Pharmaceutics)  610   121260 2021.12

    Research paper (scientific journal), Accepted,  ISSN  03785173

     View Summary

    Liposome-encapsulated methemoglobin (metHb@Lipo) has been developed as a novel antidote for cyanide poisoning. Antidotes for lethal acute poisoning should be capable of being easily stored as ready-to-use formulations without temperature restrictions. Here, we investigated the pharmaceutical stability of the metHb@Lipo suspension after one-year storage as a ready-to-use formulation at 4 °C, room temperature (23–28 °C) and 37 °C. The liposomal integrity of metHb@Lipo was observed after one year of storage at all storage temperatures with no physicochemical change or methemoglobin leakage outside the liposome. Furthermore, the encapsulated methemoglobin remained intact without aggregation, fragmentation, denaturation, or dissociation of heme. Fresh and stored metHb@Lipo were equivalent in their binding affinity against cyanide. Moreover, all one-year stored metHb@Lipo suspensions improved the mortality rates of lethal cyanide poisoning mice comparable to fresh metHb@Lipo suspension. Additionally, all stored metHb@Lipo suspensions preserved high biocompatibility, including blood compatibility and the lack of organ toxicity. In conclusion, the metHb@Lipo suspension was a pharmaceutically stable antidote for cyanide poisoning for at least one year without any temperature restrictions.

  • Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A.

    Watabe Y, Taguchi K, Sakai H, Enoki Y, Maruyama T, Otagiri M, Kohno M, Matsumoto K

    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V  2021.12

    Research paper (scientific journal), Accepted,  ISSN  0939-6411

  • An in-vitro comparative study of the binding of caspofungin and micafungin to plasma proteins.

    Yamasaki K, Sakurama K, Nishi K, Tsukigawa K, Seo H, Otagiri M, Taguchi K

    The Journal of pharmacy and pharmacology  2021.11

    Research paper (scientific journal), Accepted,  ISSN  0022-3573

  • Population pharmacokinetic analysis and dosing optimization of prophylactic fluconazole in japanese patients with hematological malignancy

    Sakamoto Y., Isono H., Enoki Y., Taguchi K., Miyazaki T., Kunimoto H., Koike H., Hagihara M., Matsumoto K., Nakajima H., Sahashi Y., Matsumoto K.

    Journal of Fungi (Journal of Fungi)  7 ( 11 )  2021.11

    Research paper (scientific journal), Accepted

     View Summary

    We conducted population pharmacokinetic (PPK) analysis and Monte Carlo simulations to determine the appropriate prophylactic dose of fluconazole to prevent invasive candidiasis in patients with hematological malignancies. Patients receiving chemotherapy or hematopoietic stem cell transplantation at Yokohama City University Hospital between November 2018 and March 2020 were included. Additionally, patients receiving oral fluconazole for prophylaxis were recruited. We set the free area under the curve/minimum inhibitory concentration (MIC) = 50 as the target and determined the largest MIC (breakpoint MIC) that could achieve more than 90% probability of target attainment. The blood fluconazole concentration of 54 patients (119 points) was used for PPK analysis. The optimal model was the one-compartment model with first-order administration and first-order elimination incorporating creatinine clearance (CLcr) as a covariate of clearance and body weight as a covariate of distribution volume. We conducted Monte Carlo simulation with fluconazole at 200 mg/day or 400 mg/day dosing schedules and patient body weight and CLcr ranging from 40 to 70 kg and 40–140 mL/min, respectively. The breakpoint MICs on the first dosing day and at steady state were 0.5–1.0 µg/mL and 1.0–2.0 µg/mL for 200 mg/day and 1.0–2.0 µg/mL and 2.0–4.0 µg/mL for 400 mg/day, respectively. The recommended dose was 400–700 mg/day for the loading dose and 200–400 mg/day for the maintenance dose. Our findings suggest that the optimal prophylactic dose of fluconazole in hematological malignancy patients depends on CLcr and body weight, and a sufficient loading and maintenance dose may be needed to completely prevent invasive candidiasis.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020.02

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    YAKUGAKU ZASSHI 138   1381 - 1389 2018

    Introduction and explanation (scientific journal), Single Work

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017

    Introduction and explanation (scientific journal), Joint Work

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017

    Introduction and explanation (scientific journal), Joint Work

  • Potential use of biological proteins for liver failure therapy.

    Taguchi K, Yamasaki K, Seo H, Otagiri M.

    Pharmaceutics. 7 ( 3 ) 255 - 274 2015

    Introduction and explanation (scientific journal), Joint Work

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

    2019.04
    -
    2021.03

    橋渡し研究戦略的推進プログラム シーズA, Other, Principal Investigator

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 田口 和明, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

    2014.04
    -
    2017.03

    科学研究費補助金・若手研究B, Research grant, Principal Investigator

  • 一酸化炭素結合型ヘモグロビン小胞体の特発性肺線維症新規治療薬としての有用性評価

    2012.04
    -
    2014.03

    科学研究費補助金・若手研究B, Research grant, Principal Investigator

Intellectual Property Rights, etc. 【 Display / hide

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Application No.: 特願2020-144044,PCT/JP2021/ 31458  2020.08 

    Patent, Joint, PCT international application

  • 横紋筋融解症治療剤

    Registration No.: 特許第6523842号  2019.05

    Patent, Joint, National application

Awards 【 Display / hide

  • 熊本大学学長賞

    2011.03

  • 日本薬学会九州支部学術奨励賞

    2017.12

  • 日本薬学会奨励賞

    2020.03

    Type of Award: Awards of National Conference, Council and Symposium

  • 日本DDS学会奨励賞 (臨床)

    2021.06, 日本DDS学会

    Type of Award: Awards of National Conference, Council and Symposium

  • 日本薬物動態学会奨励賞

    2021.11, 日本薬物動態学会

    Type of Award: International Academic Awards

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2021

  • SEMINAR (PHARMACODYNAMICS)

    2021

  • RESEARCH FOR BACHELOR'S THESIS 1

    2021

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2021

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2021

display all >>